Compare Hyatt Hotels Corporation (H) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Hyatt Hotels Corporation trades at $161.94 (market cap $15.02B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Hyatt Hotels Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.38% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hyatt Hotels Corporation for 148 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| H | HALO | |
|---|---|---|
Market Cap | $15.02B | $12.58B |
Volume | 842,340 | 2,179,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $115.22 |
52-Week Low | $135.42 | $61.63 |
Typical Hold Time | 148 Days | 1 Days |
Enterprise Value | $18.93B | $14.49B |
Dividend Yield | 0.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $161.94, up 3.05% today, near its pivot point of $159 with resistance at $162. The stock shows mixed technical signals but has consistently beaten earnings estimates in recent quarters. Revenue grew to $7.10B in 2025, though net income was negative. Analyst consensus is a Moderate Buy with a $197.77 price target, supported by recent strategic collaborations like the Delta Air Lines loyalty partnership announced September 9, 2026.
The outlook is cautiously optimistic given strong fee growth and expansion plans, but high valuation (P/E 196.83) and debt levels pose risks. Earnings momentum from Q3 2026 results, due October 29, 2026, will be critical for sustaining upside. Investors face volatility from regional economic weakness and project delays, requiring patience despite long-term growth targets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
